Cephalon/Lundbeck Discontinue Phase II/III Parkinson’s Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The compound CEP-1347 failed to demonstrate efficacy over placebo, a data monitoring committee determined. The mixed-lineage oral kinase apoptosis inhibitor was thought to prevent neuronal apoptosis. Novartis also discontinued development of a similar Phase II agent.
You may also be interested in...
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.
US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.